Cassava Sciences (SAVA) Competitors $1.44 +0.04 (+2.86%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$1.44 +0.01 (+0.35%) As of 04/17/2025 06:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SAVA vs. ZYBT, AVIR, AQST, CADL, ATXS, ALMS, MBX, ACB, DRUG, and CMPXShould you be buying Cassava Sciences stock or one of its competitors? The main competitors of Cassava Sciences include Zhengye Biotechnology (ZYBT), Atea Pharmaceuticals (AVIR), Aquestive Therapeutics (AQST), Candel Therapeutics (CADL), Astria Therapeutics (ATXS), Alumis (ALMS), MBX Biosciences (MBX), Aurora Cannabis (ACB), Bright Minds Biosciences (DRUG), and Compass Therapeutics (CMPX). These companies are all part of the "pharmaceutical products" industry. Cassava Sciences vs. Zhengye Biotechnology Atea Pharmaceuticals Aquestive Therapeutics Candel Therapeutics Astria Therapeutics Alumis MBX Biosciences Aurora Cannabis Bright Minds Biosciences Compass Therapeutics Zhengye Biotechnology (NASDAQ:ZYBT) and Cassava Sciences (NASDAQ:SAVA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, community ranking, dividends, analyst recommendations, profitability and media sentiment. Does the media favor ZYBT or SAVA? In the previous week, Zhengye Biotechnology had 1 more articles in the media than Cassava Sciences. MarketBeat recorded 1 mentions for Zhengye Biotechnology and 0 mentions for Cassava Sciences. Zhengye Biotechnology's average media sentiment score of 0.00 equaled Cassava Sciences'average media sentiment score. Company Overall Sentiment Zhengye Biotechnology Neutral Cassava Sciences Neutral Do analysts recommend ZYBT or SAVA? Cassava Sciences has a consensus target price of $54.50, indicating a potential upside of 3,684.72%. Given Cassava Sciences' stronger consensus rating and higher probable upside, analysts clearly believe Cassava Sciences is more favorable than Zhengye Biotechnology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zhengye Biotechnology 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Cassava Sciences 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Is ZYBT or SAVA more profitable? Zhengye Biotechnology's return on equity of 0.00% beat Cassava Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Zhengye BiotechnologyN/A N/A N/A Cassava Sciences N/A -88.05%-64.98% Do insiders and institutionals hold more shares of ZYBT or SAVA? 38.0% of Cassava Sciences shares are owned by institutional investors. 9.0% of Cassava Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has stronger earnings and valuation, ZYBT or SAVA? Zhengye Biotechnology has higher revenue and earnings than Cassava Sciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZhengye Biotechnology$189.75M2.50N/AN/AN/ACassava SciencesN/AN/A-$97.22M-$1.45-0.99 Does the MarketBeat Community believe in ZYBT or SAVA? Cassava Sciences received 98 more outperform votes than Zhengye Biotechnology when rated by MarketBeat users. CompanyUnderperformOutperformZhengye BiotechnologyN/AN/ACassava SciencesOutperform Votes9864.47% Underperform Votes5435.53% SummaryCassava Sciences beats Zhengye Biotechnology on 6 of the 10 factors compared between the two stocks. Get Cassava Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SAVA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SAVA vs. The Competition Export to ExcelMetricCassava SciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$69.56M$6.45B$5.30B$7.35BDividend YieldN/A3.23%5.12%4.30%P/E Ratio-1.046.8921.8017.80Price / SalesN/A231.03379.9697.74Price / CashN/A65.6738.2634.64Price / Book0.445.936.443.98Net Income-$97.22M$142.99M$3.21B$247.73M7 Day Performance13.39%4.43%2.88%1.81%1 Month Performance-48.39%-12.73%-8.63%-6.98%1 Year Performance-93.20%-9.47%11.46%1.29% Cassava Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SAVACassava Sciences3.5254 of 5 stars$1.44+2.9%$54.50+3,684.7%-93.2%$69.56MN/A-1.0430ZYBTZhengye BiotechnologyN/A$5.40+33.0%N/AN/A$254.70M$189.75M0.00278Gap UpAVIRAtea Pharmaceuticals2.3311 of 5 stars$2.95+8.9%$6.00+103.4%-19.9%$252.30MN/A-1.4370News CoverageGap DownAQSTAquestive Therapeutics1.835 of 5 stars$2.50+1.2%$10.67+326.7%-36.0%$247.18M$57.56M-5.56160Positive NewsGap UpCADLCandel Therapeutics2.286 of 5 stars$5.20+4.6%$21.00+303.8%-16.0%$245.62M$120,000.00-3.0160Short Interest ↑ATXSAstria Therapeutics1.7909 of 5 stars$4.29+6.2%$26.60+520.0%-61.7%$242.10MN/A-2.0530Positive NewsALMSAlumis2.482 of 5 stars$5.12-21.0%$26.00+407.8%N/A$241.78MN/A0.00N/AMBXMBX Biosciences2.3872 of 5 stars$7.22-2.6%$37.50+419.4%N/A$241.32MN/A0.0036Gap DownACBAurora Cannabis0.4228 of 5 stars$4.22-1.4%N/A-23.3%$237.22M$320.81M84.421,340DRUGBright Minds Biosciences2.4957 of 5 stars$33.02+14.5%$84.33+155.4%+2,804.4%$232.59MN/A-194.22N/ANews CoverageGap UpCMPXCompass Therapeutics3.3508 of 5 stars$1.68-0.8%$13.38+695.8%+14.4%$232.40M$850,000.00-4.5420Short Interest ↑ Related Companies and Tools Related Companies Zhengye Biotechnology Competitors Atea Pharmaceuticals Competitors Aquestive Therapeutics Competitors Candel Therapeutics Competitors Astria Therapeutics Competitors Alumis Competitors MBX Biosciences Competitors Aurora Cannabis Competitors Bright Minds Biosciences Competitors Compass Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SAVA) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredRead before the next tariff announcementLarry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cassava Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cassava Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SAVA Stock Free SAVA Stock Alerts